Jarushka Naidoo: Pleased to present at the WCLC24 on the use of proteomic signatures to identify immune-related toxicities

Jarushka Naidoo posted on LinkedIn:

“I was pleased to present at the International Association for the Study of Lung Cancer WCLC24 in San Diego, an Immunotherapy oral presentation on the use of proteomic signatures to identify immune-related toxicities, including specific irAEs in patients with NSCLC, and to differentiate these from those that occur from chemotherapy

We found that:

• using a 7000+ proteomic platform based an aptamer technology, that
• 3 different proteomic signatures were able to predict pts who developed toxicities
• g3+ irAEs (178 proteins)
• specific irAE (irAE-rash, 71 proteins)
• chemotherapy AEs (90 proteins)
• with minimal overlap- and link to potential immunologic mechanisms.”

Source: Jarushka Naidoo/LinkedIn

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.